{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lynparza&page=9", "query": { "intervention": "Lynparza", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 226, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lynparza&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lynparza&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T10:44:35.749Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04729387", "title": "Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 358, "start_date": "2021-07-22", "completion_date": "2026-01-19", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04729387" }, { "nct_id": "NCT05405309", "title": "RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "RP-3500", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-09-23", "completion_date": "2025-01-10", "has_results": true, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05405309" }, { "nct_id": "NCT06966700", "title": "A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Triple Negative Breast Neoplasms", "HR Low-Positive/HER2-Negative Breast Neoplasms" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2400, "start_date": "2025-06-30", "completion_date": "2034-12-29", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 64, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06966700" }, { "nct_id": "NCT04076579", "title": "Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Sarcoma Metastatic" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Trabectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 29, "start_date": "2020-03-17", "completion_date": "2024-09-26", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04076579" }, { "nct_id": "NCT03742895", "title": "Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Neoplasms" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2018-12-12", "completion_date": "2027-06-30", "has_results": true, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 24, "location_summary": "Tucson, Arizona • Fullerton, California • Los Angeles, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03742895" }, { "nct_id": "NCT02184195", "title": "Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Germline BRCA1/2 Mutations and", "Metastatic Adenocarcinoma of the Pancreas" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 154, "start_date": "2014-12-16", "completion_date": "2023-01-27", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 20, "location_summary": "Gilbert, Arizona • Orange, California • Stanford, California + 14 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02184195" }, { "nct_id": "NCT05887609", "title": "An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovary Cancer", "Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "Mirvetuximab Soravtansine-gynx", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 53, "start_date": "2023-10-03", "completion_date": "2031-01-31", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 6, "location_summary": "Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05887609" }, { "nct_id": "NCT03047135", "title": "Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 51, "start_date": "2017-03-01", "completion_date": "2027-05-01", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Omaha, Nebraska • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03047135" }, { "nct_id": "NCT03233204", "title": "Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma", "Low Grade Glioma", "Malignant Glioma", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Refractory Childhood Malignant Germ Cell Tumor", "Refractory Ependymoma", "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Glioma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma", "Rhabdoid Tumor", "Wilms Tumor" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 6, "start_date": "2017-09-14", "completion_date": "2024-06-30", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 111, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 88 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03233204" }, { "nct_id": "NCT02446600", "title": "Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Tumor", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Tumor", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 579, "start_date": "2016-03-28", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-16T10:44:35.749Z", "location_count": 337, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 256 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02446600" } ] }